fda tirzepatide compound update Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute FDA Affirms Decision on Tirzepatide

GIP receptor activation: Augments insulin secretion, promotes adipocyte lipid uptake under fed conditions, and may contribute to central appetite modulation through pathways distinct from GLP-1R

Once inside the central nervous system, research published in Open Exploration highlights that EGCg acts directly on hyperactive microglial cells, the primary drivers of neuroinflammation

This special will bring together medical experts, leaders in the space and people in the day-to-day struggle to talk about health equity and obesity with the intention to ultimately release the shame, judgment and stigma surrounding weight. GLP-1 receptor agonists, a class of drugs initially developed to treat type 2 diabetes, have been found to have significant effects on weight loss

We might be on the brink of a whole new era in brain health